Pharmacokinetics of acarbose. Part II: Distribution to and elimination from tissues and organs following single or repeated administration of [14C]acarbose to rats and dogs
- PMID: 2610718
Pharmacokinetics of acarbose. Part II: Distribution to and elimination from tissues and organs following single or repeated administration of [14C]acarbose to rats and dogs
Abstract
Acarbose (O-4,6-dideoxy-4-[[1S,4R,5S,6S)-4,5,6-trihydroxy-3- (hydroxymethyl)-2-cyclohexen-1-yl]amino]-alpha-D-glucopyranosyl- (1----4)-O-alpha-D-glucopyranosyl-(1----4)-D-glucopyranose, Bay g 5421) labelled with 14C was administered to male rats, pregnant and lactating rats as well as to female dogs with single intravenous or oral doses (2 or 4 mg.kg-1) and with repeated oral doses of 2 mg.kg-1 to male rats for 3 weeks. The distribution of radioactivity to organs and tissues, the placental transfer and the secretion into milk was studied using whole-body autoradiographic methods and/or quantitative determination of total radioactivity after autopsy. Unchanged [14C]acarbose was distributed predominantly in the extracellular space, as observed after intravenous dosing to rats. According to the main excretion route, high concentrations were found in kidneys and urine and additionally in blood, lung, and connective tissue or interstitial space. The permeability of the blood/brain barrier for [14C]acarbose and/or its metabolites was very low. No indication was found for distinct differences in the distribution patterns in rats and dogs after intravenous and also in dogs after oral administration. In contrast, in rats after oral dosing the distribution pattern of radioactivity was different with relatively high concentrations in liver, kidney, adrenal gland, spleen, and intestinal mucosa. Due to the slow absorption of the microbial degradation products of [14C]acarbose from the intestine maximum concentrations in the different tissues were reached 8-24 h after dosing.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Acarbose.2023 Aug 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Aug 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999619 Free Books & Documents. Review.
-
Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review.Arzneimittelforschung. 2001 Sep;51(9):699-725. doi: 10.1055/s-0031-1300105. Arzneimittelforschung. 2001. PMID: 11642003 Review.
-
The pharmacokinetics of nitrendipine. II. Distribution to and elimination from organs and tissues of rats and dogs after single or repeated administration of [14C]nitrendipine.Arzneimittelforschung. 1988 Nov;38(11):1599-604. Arzneimittelforschung. 1988. PMID: 3214443
-
Pharmacokinetics of nisoldipine. II. Distribution to and elimination from tissues and organs following single or repeated administration of [14C]nisoldipine to rats and dogs.Arzneimittelforschung. 1988 Aug;38(8):1099-104. Arzneimittelforschung. 1988. PMID: 3196403
-
Pharmacokinetics of acarbose. Part I: Absorption, concentration in plasma, metabolism and excretion after single administration of [14C]acarbose to rats, dogs and man.Arzneimittelforschung. 1989 Oct;39(10):1254-60. Arzneimittelforschung. 1989. PMID: 2610717
Cited by
-
Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone.Aging Dis. 2020 May 9;11(3):658-667. doi: 10.14336/AD.2019.0621. eCollection 2020 May. Aging Dis. 2020. PMID: 32489710 Free PMC article. Review.
-
Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function".J Nephrol. 2020 Feb;33(1):9-35. doi: 10.1007/s40620-019-00650-x. J Nephrol. 2020. PMID: 31576500 Free PMC article. Review.
-
Predict drug permeability to blood-brain-barrier from clinical phenotypes: drug side effects and drug indications.Bioinformatics. 2017 Mar 15;33(6):901-908. doi: 10.1093/bioinformatics/btw713. Bioinformatics. 2017. PMID: 27993785 Free PMC article.
-
Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes.Open Heart. 2015 Oct 19;2(1):e000327. doi: 10.1136/openhrt-2015-000327. eCollection 2015. Open Heart. 2015. PMID: 26512331 Free PMC article. Review.
-
Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations.Diabetes Metab Syndr Obes. 2012;5:357-67. doi: 10.2147/DMSO.S28340. Epub 2012 Oct 12. Diabetes Metab Syndr Obes. 2012. PMID: 23093911 Free PMC article.